Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent
Bon San Koo, Seokchan Hong, You Jae Kim, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo
Korean J Intern Med. 2015;30(1):104-109.   Published online 2014 Dec 30     DOI: https://doi.org/10.3904/kjim.2015.30.1.104
Citations to this article as recorded by Crossref logo
The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis
Christopher R Holroyd, Rakhi Seth, Marwan Bukhari, Anshuman Malaviya, Claire Holmes, Elizabeth Curtis, Christopher Chan, Mohammed A Yusuf, Anna Litwic, Susan Smolen, Joanne Topliffe, Sarah Bennett, Jennifer Humphreys, Muriel Green, Jo Ledingham
Rheumatology.2019; 58(2): e3.     CrossRef
Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD)
Adelle S. Jee, Tamera J. Corte
Drugs.2019; 79(14): 1511.     CrossRef
Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies
Juan Chen, Shuhong Chi, Feng Li, Jiali Yang, William C. Cho, Xiaoming Liu
Expert Opinion on Biological Therapy.2017; 17(3): 265.     CrossRef
Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist’s point of view
So-My Koo, Soo-Taek Uh
The Korean Journal of Internal Medicine.2017; 32(4): 600.     CrossRef
Adalimumab/etanercept
Reactions Weekly.2015; 1577(1): 17.     CrossRef
Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis
Shunsuke Mori
Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine.2015; 9s1: CCRPM.S23288.     CrossRef